The DUSP23 Knockout NCI-H1299 Polyclonal Cells represent a heterogeneous cell population derived from NCI-H1299 non-small cell lung carcinoma cells after CRISPR/Cas9-mediated disruption of the DUSP23 gene. As a polyclonal knockout pool, this product avoids clonal selection biases, maintaining the inherent diversity that can influence MAPK/ERK signaling dynamics. By eliminating the dual-specificity phosphatase DUSP23, which normally dephosphorylates and inactivates ERK1/2, the model provides a tool to study consequences of loss of negative regulation in a cancer-relevant background.
The parental NCI-H1299 cell line was established from a lymph node metastasis of a lung adenocarcinoma in a 43-year-old male and is characterized by TP53 null status and an epithelial-like morphology. This widely used NSCLC model exhibits genomic instability typical of p53-deficient tumors, making it a valuable platform for investigating oncogenic signaling and therapeutic vulnerabilities. When combined with DUSP23 knockout, the NCI-H1299 background creates a system where MAPK pathway deregulation can be examined in the absence of intact p53 tumor-suppressor functions.
DUSP23 encodes a dual-specificity phosphatase that selectively dephosphorylates both phosphothreonine and phosphotyrosine residues on ERK1 (MAPK3) and ERK2 (MAPK1), thereby attenuating the EGF?CEGFR?CGRB2?CSOS?CRAS?CRAF?CMEK?CERK signaling cascade. Under normal conditions, EGF stimulation triggers ERK activation, which phosphorylates transcription factors such as ELK1 and c-Fos to promote proliferation. DUSP23, itself upregulated by reactive oxygen species and EGF, serves as a feedback inhibitor, tightly controlling signal duration. In the knockout cells, loss of this brake leads to hyperactive ERK signaling, amplified downstream transcriptional responses, and potential modulation of JNK pathway cross-talk.
In NCI-H1299 cells, the absence of DUSP23 potentiates MAPK pathway output, modeling persistent ERK activity reminiscent of oncogenic mutations in NSCLC. This heightened signaling drives increased proliferation, survival, and migration, while altering sensitivity to MEK/ERK inhibitors. The model enables dissection of negative regulatory mechanisms and compensatory pathways emerging under chronic MAPK activation. Moreover, DUSP23??s responsiveness to oxidative stress links metabolic cues to kinase signaling, broadening its utility in studying redox-regulated tumor biology.
Research applications include western blotting for phospho-ERK to assess pathway activation, RT-qPCR for ELK1 and c-Fos expression, and functional assays such as MTT proliferation, wound healing migration, and xenograft tumor growth. The polyclonal population is also suitable for MEK inhibitor sensitivity assays to explore therapeutic resistance. For additional information or to discuss custom cell engineering projects, please contact Ascent Research.
